Search

Bergstrom, Kendra Gail, Karina Arambula, and Alexa Boer Kimball. 2003. “Medication Formulation Affects Quality of Life: A Randomized Single-Blind Study of Clobetasol Propionate Foam 0.05% Compared With a Combined Program of Clobetasol Cream 0.05% and Solution 0.05% for the Treatment of Psoriasis.”. Cutis 72 (5): 407-11.

Weiss, Stefan C, Kendra G Bergstrom, Sally A Weiss, and Alexa B Kimball. 2003. “Quality of Life Considerations in Psoriasis Treatment.”. Dermatology Nursing 15 (2): 120, 123-7; quiz 128.

Weiss, Stefan C, Alexa B Kimball, David J Liewehr, Andrew Blauvelt, Maria L Turner, and Ezekiel J Emanuel. 2002. “Quantifying the Harmful Effect of Psoriasis on Health-Related Quality of Life.”. Journal of the American Academy of Dermatology 47 (4): 512-8.

Kimball, Alexa Boer, and Ying Wu. 2009. “Cardiovascular Disease and Classic Cardiovascular Risk Factors in Patients With Psoriasis.”. International Journal of Dermatology 48 (11): 1147-56.

Gelfand, Joel M, Alexa B Kimball, Eliot N Mostow, Chiun-Fang Chiou, Vaishali Patel, Amy Xia, Bruce Freundlich, and Seth R Stevens. 2008. “Patient-Reported Outcomes and Health-Care Resource Utilization in Patients With Psoriasis Treated With Etanercept: Continuous versus Interrupted Treatment.”. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 11 (3): 400-7.

Kimball, Alexa B, Eric Q Wu, Annie Guérin, Andrew P Yu, Magda Tsaneva, Shiraz R Gupta, Yanjun Bao, and Parvez M Mulani. 2012. “Risks of Developing Psychiatric Disorders in Pediatric Patients With Psoriasis.”. Journal of the American Academy of Dermatology 67 (4): 651-7.e1.

Lima, X T, and A B Kimball. 2011. “Skin Carotenoid Levels in Adult Patients With Psoriasis.”. Journal of the European Academy of Dermatology and Venereology : JEADV 25 (8): 945-9.

Gordon, K B, A B Kimball, D Chau, H N Viswanathan, J Li, D A Revicki, G Kricorian, and B G Ortmeier. 2014. “Impact of Brodalumab Treatment on Psoriasis Symptoms and Health-Related Quality of Life: Use of a Novel Patient-Reported Outcome Measure, the Psoriasis Symptom Inventory.”. The British Journal of Dermatology 170 (3): 705-15.

Kimball, A B, K A Papp, Y Wasfi, D Chan, R Bissonnette, H Sofen, N Yeilding, et al. 2013. “Long-Term Efficacy of Ustekinumab in Patients With Moderate-to-Severe Psoriasis Treated for up to 5 Years in the PHOENIX 1 Study.”. Journal of the European Academy of Dermatology and Venereology : JEADV 27 (12): 1535-45.